Product logins

Find logins to all Clarivate products below.


Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)

Eisai / Biogen’s Leqembi (lecanemab) has launched for the treatment of early AD in the United States and Japan. Although EMA’s CHMP has approved the drug EC’s approval is still pending. Eli Lilly’s Kisunla (donanemab) received FDA and PMDA approval in 2024, setting the stage for intense competition as both MAbs are aimed at realizing the unfulfilled potential of a DMT for early AD. The drug also received MHRA approval but NICE rejected reimbursement for the drug, similar to Leqembi. Moreover, the drug received initial rejection from EMA’s CHMP.  We expect additional filings for maintenance IV / SC dosing and SC delivery of lecanemab (induction + maintenance) in the G7 markets. Other DMTs may soon follow in the United States and potentially other markets (e.g., Eli Lilly’s remternetug, Novo Nordisk’s semaglutide). Meanwhile, novel therapies (Axsome’s Auvelity and BMS’s Cobenfy) are progressing through late-phase development to treat the neuropsychiatric symptoms of AD. The launch of these potential blockbusters could meaningfully alter the dynamics of this market, driven by clear need, strong market demand, and premium pricing.

  • How will competition between anti-beta-amyloid (anti-) MAbs evolve in the AD market through 2033?
  • What do KOLs think of recently approved therapies (e.g., Otsuka / Lundbeck’s Rexulti) as well as key symptomatic therapies and DMTs in development for AD?
  • What is the likely uptake for Axsome’s Auvelity and BMS’s Cobenfy if they launch for AD agitation and psychosis, respectively?
  • What are the drivers of and constraints on the AD market, and how might they change over the forecast period as premium-priced agents enter the market?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents


Related Market Assessment Reports

Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Chronic Kidney Disease – Geographic Focus: China – Chronic Kidney Disease – China In-Depth (China)
Chronic kidney disease (CKD) is an irreversible condition requiring lifelong management. In China, CKD is notably widespread, particularly among older adults and those with chronic risk factors…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…